Kunena :: Тема: Posted by Benton on 30.11.2016 9:56:13: tarceva moa video (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Benton on 30.11.2016 9:56:13: tarceva moa video

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Benton on 30.11.2016 9:56:13: tarceva moa video

Страница:
1
2

ТЕМА: Posted by Benton on 30.11.2016 9:56:13: tarceva moa video

Posted by Benton on 30.11.2016 9:56:13: tarceva moa video 8 года 4 мес. назад #937

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
So you can see it it unusual to give Tarceva first and than go to chemo. It is normally the other way around.
Plenty of research has confirmed the clinical value of erlotinib as first-line treatment in NSCLC, but what about the costs of this treatment regimen? Recent data show that erlotinib may be more cost effective as a first-line treatment than standard chemotherapy for patients with EGFR-mutated advanced NSCLC.
Mark was told that chemotherapy was not effective. He was asked to take the oral drug, Tarceva which cost RM 270 / pill. The progress of the treatment responses are as follows:
alliance.pp.ua/index.php?option=com_kune...1&id=1077&Itemid=145
CYP3A4 inducers decrease erlotinib plasma concentrations and may reduce efficacy. 1,2 Pre-treatment with rifampicin for 7-11 days prior to erlotinib decreased erlotinib AUC by 58-80%. 1 Concomitant erlotinib and rifampicin (600 mg once daily for 7 days) decreased the erlotinib AUC by 69%. 2
Vassiliki Papadimitrakopoulou, M.D. from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined the effects of targeted therapies in NSCLC. Patients were randomized to four arms: erlotinib (22 patients ), erlotinib plus MK-2206 (42 patients), MK-2206 plus AZD6244 (75 patients), or sorafenib (61 patients).
HP90394 Erlotinib hydrochloride CAS 183319-69-9
microgorod24.ru/forum/ochered-1/662-post...or-pancreatic-cancer
Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
In the erlotinib-treated group (n=68), the objective response rates of cerebral and extracerebral lesions were found to be similar (29.4% vs 26.5%; P =0.134). In the pemetrexed-treated group (n=31), no statistical difference was observed between the response rates of cerebral and extracerebral lesions (12.9% vs 16.1%; P =0.525; Table 2 ). In the erlotinib-treated group (n=68), the objective control rates of cerebral and extracerebral lesions showed significant difference ( P =0.000; Table 3 ).
bus-rostov.ru/forum/razdel-predlozhenij/...-07-tarceva-ipp.html
Hola soy de Venezuela a mi papa de 57 años no fumador le diagnosticaron adenocarcinoma pulmonar metastacico y hicieron la prueba del gen mutante y salio asi MUTACION DETECTADA: DELECCION EXON 19. EGFR MUTADO. QUISIERA SABER QUE SIGNIFICA Y SI ES ALENTADOR? El recibio quimio con Alimta y avastin. Hace menos de una semana empezo con Tarceva 150mg, a cuanto tiempo se podria saber si esta haciendo efecto y cuando empezarian a salir los granos? Espero una pronta respuesta por favor.
Survival by smoking status. Like EGFR status, smoking status does not seem to be a prognostic factor for survival independent of treatment in this study, as shown in Table 3 by the comparison of smokers and nonsmokers in the placebo group (HR, 0.99; P = 0.95). In contrast, comparison of smokers and nonsmokers in the erlotinib group shows a strong effect of smoking status favoring nonsmokers (HR, 1.86; P < 0.0001).
Much Does Tarceva Cost Canada - Website of cefamore!
rakeworld.com/index.php?do=/blog/49750/p...-cancer-poumon-2012/
Tarceva (Erlotinib) Bronchialkarzinom - nichtkleinzelliges seit Juli 2008
Approximately 50 per cent of people treated with this medicine get diarrhoea as a side effect. This is usually mild. You should let your doctor know if you get diarrhoea, as you may need a medicine to control it, for example loperamide. Your dose of erlotinib may also need reducing. If you do get diarrhoea during treatment, it is important to drink plenty of fluids so that you don't get dehydrated. If you have severe or persistent diarrhoea, nausea, loss of appetite, or vomiting you should let your doctor know immediately, as your treatment may need interrupting and you may need to be treated in hospital.
The active ingredient in Tarceva is Erlotinib, and it belongs to the class of drugs called kinase inhibitors. You can buy Tarceva in the form of oral tablets.
Tarceva tabletki powlekane, 0,025 g, 30 tabl.
My Aunt was diagnosed with adenocarcinoma 4 years ago, stage 1. She underwent chemo and a lobectomy, and was in remission for 3 years. It came back with a vengence. In the meantime, her husband was diagnosed with the same cancer early last year. It metastised to the brain, we lost him 2 days after Christmas. We got my aunt to Indianapolis where my husband was treated. The Dr.s here gave her 4 months to live. The Dr. that treated my husband put her on Tarceva 4 months ago. He thought that should give her a year or so at the least. She went back 2 months ago, and the cancer is GONE. Unbelievable, right? But it is true. All of that, and I haven't even gotten to my question. I just had to share this miracle with you. Here is my question. She is still on the Tarceva. Has went through the usual side effects, nausea, fatigue, rash, diareah. For the past couple of weeks she has started passing out. This concerns me because this is what happened to her husband right before he died. My question is, has anybody who has taken this medication had this side effect? I told her she needed to contact the Dr. Thing is, he is 5 hours away from us.
Yet, even supposing a clean approval next month, Tarceva's market potential in that indication is a debatable one, given that it relies on physicians embracing the relatively new concept of maintenance therapy in NSCLC.
I never expelled anything that looked like coffee grounds. I did have mood swings, headaches and body aches. As expected, the most severe side effect was a terrible rash on my face that grew worse each day. My face was red and blotchy, punctuated by angry, painful pustules. After a week, the pain was so intense that I called my oncologist. He said I should stop taking the Tarceva immediately.
neos76.ru/index.php/component/kunena/6--...tic-cancer.html#2450
Fig A1. (A) Progression-free survival and (

overall survival in EGFR -mutant patients. E; erlotinib, ECP; erlotinib plus carboplatin and paclitaxel.
Erlotinib ( OSI-774 ) (Tarceva â ) seconde ligne Étude par voie orale à 150 mg/j ; 57 pts avec 60 % femmes, 84 % de PS 0,1, 86 % stades IV, 61 % d'adénocarcinomes, 18 %, 42 %, 21 %, 19 % ayant respectivement reçu une, deux, trois et plus de trois lignes de traitement antérieures ; CBNPC exprimant l'EGFR dans au moins 10 % des cellules tumorales ; stade IIIB-IV, en progression ou en rechute après une première ligne thérapeutique à base de sel de platine. Résultats. toxicité classique pour ce type de molécule avec rashs acnéiformes chez 50 % des pts, diarrhée chez 32 % des pts, majoritairement de grade 1 ; r éponse. RO. 12,3 % (IC 95 %. 3,8-20,

avec 1 RC et 6 RP, 15 SD ; survie médiane à 37 semaines ; survie à 1 an 48 % . La survie semble être corrélée à la sévérité des rashs cutanés. Essai ouvert chez des malades CBNPC âgés de plus de 70 ans. 150 mg/j ; taux de survie à 1 an et 2 ans. 46 % et 19 % respectivement ; corrélation entre la présence de la mutation EGFR et le résultat . Etude BR 21, 2ème ou 3 ème ligne, patients non sélectionnés. réponse objective 8,9 % vs 1 % pour le placebo ; survie jusqu'à progression. 2,2 vs 1,8 mois (Shepherd, 2005). Etude de phase IV (TRUST). 7000 patients mais pas de bras de contrôle ; contrôle global de la maladie (70 %). première ligne Association. patients non sélectionnés. TRIBUTE (Tarceva Responses in conjunction with paclitaxel and carboplatine) ; docetaxel ; docetaxel + carboplatine. taux de réponse très faible (Herbst, 2005). TALENT (Tarceva lung cancer investigation) ; cisplatine + gemcitabine. taux de réponse très faible. Monothérapie. patients sélectionnés : Essai sur NSCLC IIIB avec épanchement pleural ou IV porteurs des mutations EGFR. amélioration du taux de réponse (71 %) et du suivi médian sans progression (14 mois) chez les sujets porteurs de dél19, âgés de 61 à 70 ans (Rosell, 2009). Monothérapie. patients non sélectionnés : Essai de phase 3 contre placebo sur NSCLC stade IIIb ou IV en contre-indication de chimiothérapie. légère augmentation de la survie sans progression (2.8 vs 2.6 mois) ; seul facteur pronostic indépendant associé significativement à la survie globale. rash lors du premier cycle (erlotinib + rash. survie globale médiane. 6.2 mois ; survie à un an. 24 % (Lee, 2012). Monothérapie. maintenance NSCLC stade IIIb (et intolérant à une polychimiothérapie) ou IV, score ECOG 0-1. comparé à un placebo, erlotinib prolonge la survie sans progression et la survie globale de 41 % (HR. 0.71 ; IC 95 %. 0.62-0.82 ; p < 0.0001) et 23 % (HR. 0.81. IC 95 %. 0.7-0.95 ; p < 0.009) respectivement, la survie sans progression est un peu plus longue chez les patients mutés EGFR (45 %), sans détérioration de la qualité de vie (Juhasz, 2013).
This medicine is not meant to be taken by pregnant women, as it may cause serious harm to the unborn child. Use an effective contraceptive during Tarceva treatment, and also for 2 weeks after the completion of treatment.
forum.drujba-konserv.com/viewtopic.php?p=12535#12535
The metabolism of Erlotinib can be decreased when combined with Terbinafine.
Overall, erlotinib 150 mg daily was well tolerated by most patients. Dose reduction to 100 mg was needed in 15% of erlotinib-treated patients and further to 50 mg in 4% of patients, compared with 1% and <1% in placebo-treated patients. Discontinuation due to protocol toxicity occurred in 5% in the erlotinib arm and 2% in the placebo arm.
laptop31.ru/forum/zayavi-o-sebe/853-post...ncreatic-cancer.html
Highly Recommended CAS#183319-69-9 Erlotinib Hydrochlorid
Biologically targeted agents have emerged as important treatment options in advanced head and neck cancer.7 Approximately 80% to 90% of head and neck squamous cell carcinomas (HNSCCs) demonstrate elevated EGFR, and approximately 10% of patients respond to anti-EGFR monotherapy.8. 9 It is noteworthy that, relative to chemotherapy, these agents have a favorable toxicity profile with no significant enhancement of radiation-induced mucosal toxicity.10 Although the monoclonal antibody cetuximab is the best studied agent, small-molecule EGFR tyrosine kinase inhibitors (TKIs) have demonstrated similar activity rates in the recurrent and metastatic settings.11. 12 In addition to the advantages of convenient oral administration, anti-EGFR TKIs can circumvent certain mechanisms of ligand-independent EGFR mutations.13 Like EGFR, cyclooxygenase-2 (COX-2) is another overexpressed marker in HNSCC that correlates with a poor prognosis. Indeed, previous studies have characterized downstream crosstalk between the 2 molecules, and the preclinical use of EGFR TKIs combined with COX-2 inhibitors have demonstrated additive efficacy in inhibiting the growth of HNSCC cell lines. With the objective of enhancing response to EGFR inhibitors, a recent phase 1 trial from the Dana-Farber Cancer Institute demonstrated a 22% response rate to concurrent gefitinib and celecoxib with minimal toxicity.14 On the basis of these data, along with supporting preclinical data from our laboratory and others, we designed a phase 1 trial to assess the feasibility and tolerability of combined erlotinib, celecoxib, and reirradiation.7. 15
Tarceva, also known as erlotinib, is marketed by Roche and OSI Pharmaceuticals. It is approved as a second-line treatment for advanced non-small cell lung cancer (NSCLC) and for combination therapy for first-line advanced pancreatic cancer.